Danish foundation data show endometriosis research received EUR 173,958 versus EUR 254.9 million for diabetes, while a mouse study reports a tweaked niclosamide reversed lesion-induced macrophage changes

The npj Women's Health analysis counted funding from Denmark's top 100 grant-awarding foundations up to 2023 and found EUR 173,958 for endometriosis research versus EUR 254,908,430 for diabetes and EUR 325,940 for inflammatory bowel disease, with only nine of the 100 foundations supporting one or more of the three conditions. It extends an earlier, largely US-based comparison of endometriosis underfunding to a Danish foundation-funding setting and adds media mentions as a proxy for awareness. Aggregated grant amounts drawn from foundation feedback or published grant information, presented with a funding-flow figure; media mentions come from Infomedia searches covering 1992 to 2023, with 201,255 mentions for diabetes, 2,621 for endometriosis and 4,384 for inflammatory bowel disease.

The same analysis reports that endometriosis affects approximately 190 million women globally, that diagnosis is delayed on average by 7-9 years and has stayed so for a decade, that only up to 2% of reproductive-age women in Denmark receive a diagnosis, and that affected individuals use the Danish healthcare system 19% more often in the ten years before diagnosis. It places the funding gap alongside measurable clinical and health-service burden rather than treating underfunding as an isolated budget question. Cites WHO fact sheets, a Danish population-based registry study and a Danish case-control study; the article states that no datasets were generated or analysed for the study itself.

The Communications Biology mouse study used single-cell transcriptomics of peritoneal immune cells to identify three intermediate macrophage subtypes, IM1 to IM3, beyond the classical small and large peritoneal macrophages, and reports that lesion induction enhanced differentiation of recruited macrophages, promoted replenishment of resident LPMs and increased ablation of embryo-derived LPMs, all stepwise suppressed by niclosamide. Relative to a framework centred on SPM and LPM subsets, it provides transcriptomic identities for intermediate subtypes and maps drug effects onto specific differentiation steps. Single-cell sequencing of 13,679 cells across three treatment groups, with flow cytometry and RT-qPCR on independent samples confirming key gene changes; trajectory analysis used Monocle 3 and gene function was probed with scTenifoldKnk in silico knockout.

The study further reports that niclosamide restored macrophage-to-B-cell communication disrupted by lesion induction, reflected in recovered Cxcl13 and C3 expression, while transcriptomic changes in B cells themselves were minimal, leading the authors to propose macrophages as a possible direct target of niclosamide. It moves the drug's action from general anti-inflammation toward restoration of a specific intercellular signalling axis involving CXCL13, C3 and B1a, B1b and B2 cells. Based on CellChat-inferred ligand-receptor interactions, with 23 significantly expressed ligand-receptor pairs identified; the authors state in the discussion that validation of similar macrophage pathogenesis in human patients is still needed.

The mouse study's conclusions apply to the peritoneal environment of lesion-induced C57BL/6J mice given oral niclosamide at 200 mg/kg/day for three weeks; the authors propose macrophages as a possible direct target of niclosamide and state that similar macrophage differentiation and replenishment processes must be validated in human patients before clinical use can be supported. The Danish funding analysis applies to the funding landscape of Denmark's top 100 grant-awarding foundations up to 2023, compares endometriosis with diabetes and inflammatory bowel disease, and draws media mentions from Infomedia searches covering 1992 to 2023, so its conclusions are scoped to the Danish funding and media setting rather than global totals.

In the mouse study, key gene functions rest on in silico knockout, and the authors state in the discussion that the biological functions of Retnla, Cfb and Timd4 still need in vivo knockout studies and that clear direct binding targets of niclosamide have not been identified. The subtype-specific contributions of macrophage populations in human pelvic cavity and endometrial tissues remain unclear, as do the roles of B and T cells and their communication with macrophages. On the funding side, the article states that no datasets were generated or analysed, its figures come from foundation feedback or public information limited to Denmark's top 100 foundations, and global funding patterns and patient-level causal effects remain open questions. In addition, the loaded news story is truncated at a paywall, so its full description of the tweaked niclosamide chemistry and the mouse results could not be read, and the specific design details and efficacy data of the modified drug cannot be summarized here.